About this Research Topic
Among all types of omics, genomics and transcriptomics based on next-generation sequencing technology, and metabolomics and proteomics based on high-resolution mass spectrometry have been widely used and already played an important role in oncological research, cancer diagnosis and treatment. Radiomics represents an merging new type of omics technology and is profoundly changing the diagnosis mode of tumor in digitization and intelligence. The theme of this research topics is to highlight the innovative research and application of these well established as well as emerging or new omics technologies with a aim to cross-hybridize multiomic data for creative and innovate clinical oncology.
In this research topic, we will focus on the application and innovation of multiomics technologies in clinical oncology. We welcome submissions of Original Research papers and Reviews focusing on but not limited to:
- Clinical oncology research and development of tumor diagnosis technology based on metabonomics.
- Precision clinical oncology research based on transcriptomics or genomics.
- Application Research of clinical oncology based on proteomics.
- Application report of tumor diagnosis technology scheme based on radiomics.
- Comprehensive clinical oncology research combined with multiomics techniques.
- Innovation of new omics technology or improvement of original technology.
- Application of artificial intelligence in multiomics data interpretation
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: omics, genomics, transcriptomics, metabonomics, proteomics, radiomics, clinical oncology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.